Obesity drug VCT220 put to the test: will common meds interfere?
NCT ID NCT07056842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how two common drugs—rifampin and itraconazole—change the way the body processes VCT220, a new medicine being developed for obesity. Thirty-two healthy adults took VCT220 alone and then with each of these drugs to see if their levels in the blood changed. The goal was to understand potential drug interactions, not to treat obesity directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, 250014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Low-Calorie diet and Weight-Loss drug send type 2 diabetes into remission?
- Pedal-Assist E-Bikes may boost fitness and cut fat in sedentary students
- New program helps seniors in camden fight obesity and pain without drugs
- Exercise boosts Weight-Loss surgery results, study finds
- New obesity drug VCT220 put through drug interaction tests
- 3D-Printed device could make breathing tubes safer for obese patients